OncoVista Innovative Therapies, Inc. Subsidiary AdnaGen Inks Exclusive Agreement with TATAA Molecular Diagnostics

Published: Jan 26, 2010

SAN ANTONIO--(BUSINESS WIRE)--OncoVista Innovative Therapies, Inc. (OTCBB:OVIT) announced today that its wholly owned subsidiary, AdnaGen AG, the manufacturer of CE-certified circulating tumor cell (CTC) diagnostic assays, has entered into an agreement with TATAA Molecular Diagnostics, for the exclusive use of its Adnatest™ BreastCancer assays in an international breast cancer research COHERTA project. TATAA Molecular Diagnostics and its partner, the Institute of Biotechnology of the Czech Academy of Science, are funding the COHERTA study through a grant obtained from the Czech and Slovak subsidiaries of Hoffmann-La Roche the global drug manufacturer.

Back to news